A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options

Launched by AXOGEN CORPORATION · Jul 28, 2009

Keywords

ClinConnect Summary

The CHANGE study is a post-marketing study designed as a prospective, single-blind, randomized, two phase study comparing clinical outcomes of AVANCE Nerve Graft to hollow tube conduits. The first phase (pilot phase) assesses projected differences expected between two treatment groups. The second phase of the study provides comparison data between the two treatment groups.

AVANCE Nerve Graft is current regulated in the United States as a 361 HCT/P Tissue for transplantation; not a Drug, Biologic, or Medical Device. Hollow tube conduits are currently regulated in the United States as medica...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Require primary or secondary nerve injury repair with Hollow Nerve Conduit or AVANCE™ in at least 1 digital nerve;
• • Undergo End to End nerve to nerve graft coaptation on both the proximal and distal portion of the nerve gap in the AVANCE™ group or nerve entubulation in the Hollow Nerve Conduit group;
• • Be willing to comply with all aspects of the treatment and evaluation schedule over a 12 Month duration; and
• • Sign and date an IRB-approved written informed consent prior to initiation of any study procedures, including screening procedures.
• Exclusion Criteria:
• • Nerve gaps of \< 5 mm or \> 20 mm;
• • Estimated distance of regeneration of \>125 mm (distance from injury site to sensory target)
• • Nerve crush or avulsion injuries;
• • Incomplete nerve transections;
• • Injury requiring replantation of target digit;
• • Contralateral digital injuries corresponding to the target digit;
• • Nerve injuries in the affected limb proximal to the crease of the wrist;
• • End to side nerve repair;
• • Injuries with significant vascular damage which may impair adequate perfusion of the target limb;
• • Subjects who are undergoing treatment with chemotherapy, radiation therapy, or other know treatment which affects the growth of neural and/or vascular system;
• • Use of bovine collagen based hollow nerve conduit in a subject with known or suspected bovine sensitivity;
• • Subjects age ≤18 years or ≥70 years;
• • History neuropathy, diabetic or any other known neuropathy;
• • Secondary nerve repair \>12 weeks post initial injury;
• • Currently enrolled in another investigational study;
• • Expected use of medications during the study that are known to cause peripheral neuropathy;
• • History or Reynaud's or other disorder known to compromise circulation or sensation in the upper extremity; and
• • Any subject who at the discretion of the Investigator is not suitable for inclusion in the study.